** Shares in Laboratorios Rovi ROVI.MC fall 16%, set for their worst day in nearly 15 years, after the Spanish pharmaceutical company said it expected its 2024 EBITDA to come lower than market consensus
** It forecasts its 2024 EBITDA to be between 10% and 15% lower than 2024 EBITDA levels expected by market consensus, due to anticipated lower activity in its contract manufacturing $(CDMO)$ business in Q4
** Rovi also said it maintains its guidance for 2025
** "We expect a negative reaction because the impact on EBITDA is relevant and because it will once again raise doubts about its CDMO business, which today is the most relevant," says Sabadell broker in a note
** The lower demand of Covid-19 vaccines from Moderna MRNA.O, that Rovi manufactures, would be the main reason for the lower activity in Q4, says a Renta 4 analyst
** The company is due to report its full year results on February 25
** Shares at their lowest level since December 2023
(Reporting by Joao Manuel Mauricio)
((JoaoManuel.VicenteMauricio@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。